Amar Sawhney
CEO
Instylla
Instylla develops next-generation liquid embolics specifically designed for interventional radiology, targeting applications in interventional oncology and peripheral hemostasis. Their technology provides a precise and effective solution for occluding blood vessels, enhancing treatment outcomes for patients with hypervascular tumors.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$63.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current liquid embolic treatments for interventional radiology often require active management by interventional radiologists due to shortcomings such as failure to deeply penetrate the tumor vascular bed, inadvertent delivery into healthy vessels, dependence on blood coagulation, inefficient embolic preparations, and procedural complexity. These issues can lead to continued tumor blood flow, non-target embolization, delayed occlusion, and the need for rigorous training and expertise.
Solution
Instylla develops next-generation liquid embolics, including the Embrace Hydrogel Embolic System (HES), designed for interventional radiology applications in interventional oncology and peripheral hemostasis. Embrace HES consists of two low viscosity liquid precursors that, when mixed with iodinated contrast media, polymerize intravascularly to form a soft, water-based PEG hydrogel. This hydrogel casts out the vasculature to create a rapid and durable occlusion, independent of the patient’s coagulation status. Over approximately 11 months, the hydrogel liquifies via hydrolysis, and the hydrolysis products are absorbed and cleared via renal filtration.
Target Audience
The primary target audience includes interventional radiologists specializing in interventional oncology and peripheral hemostasis.
Features
- Two-component liquid embolic system that polymerizes in situ to form a hydrogel.
- Water-based PEG hydrogel composition with no organic solvents.
- Can be mixed with commercially available iodinated contrast media for radiopacity.
- Designed for deep, distal penetration into the vasculature.
- Promotes rapid and durable occlusion.
- Hydrogel liquifies via hydrolysis over approximately 11 months with clearance via renal filtration.
- Delivery Kit available for optimized preparation and administration.